Importantly, the landscape also yields clues towards potential drug targets (FLT3, NAALAD2, CX3CL1-CX3CR1, OPRM1, and HRH2) that can be further developed into TD treatments. This evidence concerns the gene FLT3 and thanatophoric dysplasia.